Since Hsp90 has been a promising anti-tumor target and several Hsp90 inhibitors have been used in clinical trials (Goldman et al., 2010; Demetri et al., 2011; Dickson et al., 2012), the function of Hsp90α in the retina raises concern for developing drugs indiscriminatingly targeting both Hsp90 isoforms. Here, HSP90AB1 is linked to neoplasm.